|
1.
|
|
|
Isotope release studies from nanostructured target materials
/ Berlin, Valentina (CERN, CH-1211 Geneva 23, Switzerland) ; Au, Mia (CERN, CH-1211 Geneva 23, Switzerland) ; Ajayakumar, Anjali (CERN, CH-1211 Geneva 23, Switzerland) ; Berbalk, Justus (CERN, CH-1211 Geneva 23, Switzerland, KU Leuven, Leuven, Belgium) ; Chrysalidis, Katerina (CERN, CH-1211 Geneva 23, Switzerland) ; Frank, Isabel (CERN, CH-1211 Geneva 23, Switzerland) ; Giesel, Paul Florian (CERN, CH-1211 Geneva 23, Switzerland, Universität Greifswald, Greifswald, Germany) ; Grasser, Matthias Alexander (CERN, CH-1211 Geneva 23, Switzerland) ; Heinke, Reinhard (CERN, CH-1211 Geneva 23, Switzerland, University of Manchester, Manchester, UK) ; Kalnina, Patricija (CERN, CH-1211 Geneva 23, Switzerland, Latvijas Universitāte, Rīga, Latvia) et al.
CERN-INTC-2025-003 ; INTC-I-282.
-
2025 - mult..
Full text
|
|
|
2.
|
|
|
3.
|
“Particle therapy - future for the Baltic states?” – synthesis of the expert workshop report
/ Paļskis, Kristaps (Riga Tech. U. ; CERN) ; Korobeinikova, Erika ; Bogorada-Saukuma, Dace ; Camarda, Anna Maria (CNAO, Milan) ; Taylor, Rebecca (CERN ; Imperial Coll., London) ; Benedetto, Elena ; Mamis, Edgars (CERN ; Latvia U.) ; Radziņa, Maija ; Ērglis, Andrejs (Latvia U.) ; Adliene, Diana et al.
Background Baltic States remains one of the few regions in the Europe without a dedicated particle therapy center. An initiative since 2021 has been started by CERN Baltic Group on a novel particle therapy center development in the region in partnership with CERN NIMMS collaboration. [...]
2024 - 8 p.
- Published in : Health Technol. 14 (2024) 965-972
Fulltext: PDF;
|
|
|
4.
|
Target Development towards First Production of High-Molar- Activity $^{44g}$Sc and $^{47}$Sc by Mass Separation at CERN-MEDICIS
/ Mamis, Edgars (CERN ; Latvia U.) ; Duchemin, Charlotte (CERN) ; Berlin, Valentina (CERN) ; Bernerd, Cyril (CERN) ; Bovigny, Mathieu (CERN) ; Chevallay, Eric (CERN) ; Crepieux, Bernard (CERN) ; Gadelshin, Vadim Maratovich (Mainz U., Inst. Phys.) ; Heinke, Reinhard (CERN) ; Hernandez, Ronaldo Mendez (CERN ; Havana, ISCTN) et al.
The radionuclides 43Sc, 44g/mSc, and 47Sc can be produced cost-effectively in sufficient yield for medical research and applications by irradiating natTi and natV target materials with protons. Maximizing the production yield of the therapeutic 47Sc in the highest cross section energy range of 24–70 MeV results in the co-production of long-lived, high-γ-ray-energy 46Sc and 48Sc contaminants if one does not use enriched target materials. [...]
2024 - 28 p.
- Published in : Pharmaceuticals 17 (2024) 390
Fulltext: PDF;
|
|
|
5.
|
Scandium thermal release from activated natTi and natV target materials in mixed particle fields: Investigation of parameters relevant for isotope mass separation
/ Mamis, E (CERN ; Latvia U.) ; Kalnina, P (CERN ; Latvia U.) ; Duchemin, C (CERN) ; Lambert, L (CERN) ; Conan, N (CERN) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Froeschl, R (CERN) ; Ruiz, F Ogallar (CERN) ; Theis, C (CERN) et al.
Scandium (Sc) has gained significant interest in nuclear medicine due to its 43Sc, 44g/mSc, and 47Sc radioactive isotopes being suitable for cancer diagnostics and therapy, offering a promising avenue for theranostics. Various production methods, including irradiation of enriched or naturally abundant calcium (Ca), titanium (Ti), and vanadium (V) materials with different particle beams, have been investigated to produce 43Sc, 44g/mSc, and 47Sc. [...]
2024 - 10 p.
- Published in : Nucl. Instrum. Methods Phys. Res., B 553 (2024) 165400
Fulltext: PDF;
|
|
|
6.
|
CERN-MEDICIS: Operational indicators to support the production of new medical radionuclides by mass-separation
/ Stora, T (CERN) ; Duchemin, C (CERN) ; Andreazza, W (CERN) ; Aubert, E (CERN) ; Bernerd, C (CERN ; Leuven U.) ; Cocolios, T (Leuven U.) ; Deschamps, M (CERN) ; Dorsival, A (CERN) ; Duraffourg, M (CERN) ; Fedosseev, V (CERN) et al.
CERN-MEDICIS is an isotope mass separation facility for biomedical R&D; located in a class A laboratory, receiving up to 50% of the 1.4GeV PSB protons. It was commissioned with radioactive ion beams in 2017. [...]
2023 - 6 p.
- Published in : J. Phys. : Conf. Ser.: 2687 (2024) , no. 8, pp. 082039
- Published in : JACoW IPAC: 2023 (2023) , pp. WEPM125
Fulltext: PublicationJACoW - PDF; PublicationIOP - PDF;
In : 14th International Particle Accelerator Conference (IPAC 2023), Venice, Italy, 7 - 12 May 2023, pp.082039
|
|
|
7.
|
Novel radionuclides for use in Nuclear Medicine in Europe: where do we stand and where do we go?
/ Radzina, Maija (Latvia U. ; CERN) ; Saule, Laura (Latvia U.) ; Mamis, Edgars (Latvia U. ; CERN) ; Koester, Ulli (Laue-Langevin Inst.) ; Cocolios, Thomas Elias (Leuven U.) ; Pajuste, Elina (Latvia U.) ; Kalnina, Marika (Unlisted) ; Palskis, Kristaps (CERN ; Riga Tech. U.) ; Sawitzki, Zoe (Leuven U.) ; Talip, Zeynep (PSI, Villigen) et al.
Background
In order to support the ongoing research across Europe to facilitate access to novel radionuclides, the PRISMAP consortium (European medical radionuclides programme) was established to offer the broadest catalog of non-conventional radionuclides for medical and translational research. The aim of this article is to introduce readers with current status of novel radionuclides in Europe.
Main body
A consortium questionnaire was disseminated through the PRISMAP consortium and user community, professional associations and preclinical/clinical end users in Europe and the current status of clinical end-users in nuclear medicine were identified. [...]
2023 - 16 p.
- Published in : EJNMMI Radiopharm. Chem. 8 (2023) 27
Fulltext: PDF;
|
|
|
8.
|
|
alerte email personnalisée
ou inscrivez-vous via le 
flux RSS.